Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

17.08$1.09 6.82%
At close       04:00 PM   

Stock Snapshot

15.99
Prev. Close
16.30
Open
492.25M
Market Cap
499640.00
Number of Shares
16.08
Day Low
17.50
Day High
17.08
-
P/E Ratio
25.10M
Free Float in %
-0.53
EPS 2021
3.15
Book Value per Share
2.59
Cash Flow per Share
PDS Biotechnology Corporation (PDSB)
PDS Biotechnology Corporation (PDSB) stock rallied over 6.82% intraday to trade at $17.08 share on NASDAQ. The stock opened with a gain of % at $16.30 and touched an intraday high of $17.50, rising 9.44% against the last close of $15.99. The stock went to a low of $16.08 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$15.66$15.30$15.96$15.30278,227
2021-09-03$16.00$15.47$16.02$14.9051,000,000
2021-09-02$15.30$15.99$16.14$15.1046,300,000
2021-09-01$15.55$15.30$15.81$15.1137,670,000
2021-08-31$14.95$15.55$15.97$14.1179,050,000
2021-08-30$14.50$14.92$15.40$14.4967,630,000
2021-08-27$14.01$14.45$14.97$13.8571,160,000
2021-08-26$13.29$13.89$14.13$13.2168,830,000
2021-08-25$12.51$13.52$13.73$12.2392,500,000
2021-08-24$11.44$12.45$12.65$11.3794,380,000
2021-08-23$10.46$11.27$11.37$10.2756,690,000
PDS Biotechnology Corporation
303A College Road East
Princeton, NJ 08540
United States

http://www.pdsbiotech.com
800 208 3343
Employees
15
Sector
Healthcare
Sales or Revenue
-
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30

PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam